Key result
Activated protein C reduces endothelial leukocyte adhesion and organ damage markers in endotoxemic rats.
Why the study?
Vascular endothelial abnormalities play an important role in septic organ dysfunction, motivating an evaluation of the effect of recombinant human activated protein C on leukocyte-endothelial interaction in endotoxemia.
Does recombinant human activated protein C improve visceral microcirculation and attenuate leukocyte-endothelial interaction in a rat model of lipopolysaccharide-induced endotoxemia?
Does recombinant human activated protein C improve visceral microcirculation and attenuate leukocyte-endothelial interaction in a rat model of lipopolysaccharide-induced endotoxemia?
Answers are grounded in this paper and cite their sources.
In a rat model of endotoxemia, recombinant human activated protein C protects visceral microcirculation and reduces organ damage markers by inhibiting leukocyte-endothelial interaction and suppressing inflammatory cytokines, with low-dose treatment showing fewer bleeding events than high-dose.
Objective Abnormalities in the vascular endothelial function play an important role in the development of septic organ dysfunction. The aim of the study was to examine the effect of recombinant human activated protein C on leukocyte-endothelial interaction in endotoxemia. Design Experimental animal model of sepsis. Setting University research laboratory. Subjects Normal Wistar rats. Each animal was infused with 4.5 mg/kg lipopolysaccharide to simulate severe sepsis. Interventions Rats were injected with endotoxin simultaneously with either a low or a high dose of recombinant human activated protein C (n = 7). One, 2, and 3 hrs after injection, mesenteric microcirculation was observed under intravital microscopy. In another series, tumor necrosis factor, interleukin-6, alanine transaminase, and blood urea nitrogen levels were evaluated (n = 5). Measurements and main results The adhesive leukocyte count on the endothelium was significantly suppressed in both high-dose and low-dose groups (p < .01 and .05, respectively). The bleeding events decreased in the low-dose treatment group compared with both the control (p < .05) and high-dose group (p < .05). Microcirculatory flow as expressed by red blood cell velocity was maintained better in the low-dose group. Comparison of cytokine levels showed a significant decrease in the treatment groups. Organ damage markers were also suppressed in the treatment groups (p < .05) Conclusions Recombinant human activated protein C demonstrated a protective effect on microcirculation through the inhibition of leukocyte-endothelial interaction and suppression of inflammatory cytokine production.
No takes yet. Share an insight, caveat, or question.
Iba et al. (2005) studied Severe sepsis / endotoxemia (rat lipopolysaccharide model). Recombinant human activated protein C vs. Control (endotoxin only) was evaluated on Adhesive leukocyte count on the endothelium in mesenteric microcirculation (p=<0.01 (high-dose), <0.05 (low-dose)). Recombinant human activated protein C suppressed adhesive leukocyte counts in endotoxemic rats at high and low doses, reducing organ damage markers.
Synapse has enriched 10 related papers. Consider them for comparative context: